07/06/2026
ADVANTAGES OF LOSARTAN
URIC ACID LOWERING EFFECTS
Decreases uric acid: the only ARB with uricosuric activity; this causes
i) Decreases platelet aggregation and endothelial dysfunction
ii) Increases insulin sensitivity
iii) Prevention of diabetes by increasing serum adiponectin levels
iv) Reduces blood pressure, serum uric acid levels and daily urinary protein excretion in diabetic and nondiabetic, proteinuric and hypertensive patients
v) Prevents risk in uric acid induced by thiazide diuretics
vi) Attenuates the increase in SUA over 4.8 years as observed in the life study
vii) Reduces serum uric acid ?(SUA) in dose dependent manner in doses ranging from 25-100 mg
viii) The effect is due to the parent molecule, not its metabolite, action is unrelated to ATII
ARB CHANGE IN URIC AICD
Losartan -0.12
Valsartan +0.19
Telmisartan +0.15
Candesartan +0.15
Olmesartan +0.17
CVS
Decreases LVH
29% reduction in CV events in the Losartan as compared to Atenolol: LIFE study
In hypertensive patients with LVH, Losartan reduces myocardial fibrosis unlike Atenolol
Prevents arrhythmias associated with LVH, drug of choice in LVH in hypertension and diabetes
Reduces the incidence of new onset diabetes in diabetic patients
Decreases new onset of atrial fibrillation, proven mortality benefits
Improves exercise tolerance in patients with moderate mitral regurgitation
Protects against atherosclerosis in young patients with risk factors other than hypertension
Able to reverse the blood pressure increase from diet-induced obesity
Beneficial in isolated systolic hypertension [ISH]
Reduction in incidence of stroke
Improves exercise tolerance, causes lower heart rate and ventilation requirements in LV systolic dysfunction
Reduces mortality by 60%
Reduces 32% risk of first hospitalization for heart failure
BP reduction by 12/6 mmHg
METABOLIC SYNDROME
Beneficial effect is found in following metabolic syndrome parameters: waist circumference, BMI, TC, and uric acid
UROGENITAL SYSTEM
Reduces albuminuria by 33%
No erectile dysfunction
Regresses the progression of nephropathy
Antiaggregant
PPAR-gamma agonist effect
Reduces the progression of ESRD by 28%
Reduces the incidence of doubling of serum creatinine by 25%
Albuminuria reduction by 48%
